13:12:51 EST Sun 17 Feb 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:EOLS from 2018-02-16 to 2019-02-15 - 39 items News ReleasesIn The NewsOther
DateSymPriceTypeHeadline
2019-02-04 06:00EOLSNews ReleaseEvolus to Hold Conference Call Following Jeuveau ™ FDA Approval
2019-02-01 16:58EOLSNews ReleaseEvolus Receives FDA Approval for Jeuveau ™ prabotulinumtoxinA-xvfs for Injection
2018-12-19 08:01EOLSNews ReleaseEvolus Added to NASDAQ Biotechnology Index
2018-12-11 07:50EOLSNews ReleaseInvestor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence
2018-12-03 09:25EOLSNews ReleaseALPHAEON repays outstanding principal amount under its secured convertible notes due December 23, 2018
2018-11-19 05:30EOLSNews ReleaseEvolus Receives Conditional FDA Acceptance of Jeuveau ™ Brand Name
2018-11-05 16:05EOLSNews ReleaseEvolus Reports Third Quarter 2018 Financial Results
2018-11-01 08:01EOLSNews ReleaseEvolus to Participate in Two Upcoming Investor Conferences
2018-10-22 16:01EOLSNews ReleaseEvolus Expands Leadership Team with Appointments of Key Executives
2018-10-22 08:10EOLSNews ReleaseDetailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare, and Frontline — What Drives Growth in Today's Competitive Landscape
2018-10-18 08:01EOLSNews ReleaseEvolus to Release Third Quarter 2018 Financial Results on Monday, November 5, 2018
2018-09-20 16:01EOLSNews ReleaseEvolus to Present at the Cantor Global Healthcare Conference
2018-09-05 08:01EOLSNews ReleaseEvolus Appoints Ashwin K. Agarwal as Vice President, Finance, Investor Relations and Treasury
2018-08-29 08:01EOLSNews ReleaseEvolus Receives Acceptance of FDA BLA Resubmission for DWP-450
2018-08-17 08:01EOLSNews ReleaseEvolus Granted Approval of DWP-450 by Health Canada
2018-08-15 08:05EOLSNews ReleaseEvolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D
2018-08-15 08:01EOLSNews ReleaseEvolus, Inc. Announces Full Exercise and Closing of Underwriters ’ Overallotment Option
2018-08-02 07:30EOLSNews ReleaseEvolus Reports Second Quarter 2018 Financial Results
2018-08-02 07:25EOLSNews ReleaseEvolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450
2018-07-26 16:01EOLSNews ReleaseEvolus to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
2018-07-18 22:20EOLSNews ReleaseEvolus, Inc. Announces Pricing of Public Offering of Common Stock
2018-07-16 16:01EOLSNews ReleaseEvolus, Inc. Announces Proposed Public Offering of Common Stock
2018-06-22 09:34EOLSNews ReleaseClinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018
2018-06-18 08:01EOLSNews ReleaseEvolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer
2018-06-14 08:01EOLSNews ReleaseEvolus to Participate in Two Upcoming Investor Conferences
2018-06-04 08:01EOLSNews ReleaseEvolus to Present at the Jefferies 2018 Global Healthcare Conference
2018-05-29 07:30EOLSNews ReleaseEvolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development
2018-05-16 12:56EOLSNews ReleaseINVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer
2018-05-16 08:30EOLSNews ReleaseEvolus Announces Progress with DWP-450 Regulatory Submissions
2018-05-16 07:01EOLSNews ReleaseEvolus to Provide Regulatory Update on Wednesday, May 16, 2018
2018-05-10 16:01EOLSNews ReleaseEvolus Reports First Quarter 2018 Financial Results
2018-05-07 07:01EOLSNews ReleaseEvolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer
2018-05-03 08:01EOLSNews ReleaseEvolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
2018-04-23 07:30EOLSNews ReleaseEvolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS ’ The Aesthetic Meeting
2018-04-05 07:30EOLSNews ReleaseEvolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox ® Meets Primary Endpoint
2018-03-29 07:30EOLSNews ReleaseEvolus Reports Fourth Quarter and Full Year 2017 Financial Results
2018-02-22 11:21EOLSNews ReleaseEvolus, Inc. (Nasdaq: EOLS) to Ring The Nasdaq Stock Market Closing Bell
2018-02-17 15:00EOLSNews ReleaseEvolus Announces Presentation of Phase III European - Canadian Comparative Data
2018-02-16 12:31EOLSNews ReleaseEvolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA